CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines.

There are estrogen receptors in your breast tissue, which means a drop in estrogen can lead to breast changes, Dr. Streicher ...

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms ...

1 The first and only non-hormonal NK3 antagonist indicated for ... safe and efficacious tool to help mitigate the burden of hot flashes and night sweats." Menopause is a natural stage of aging ...

due to rare but serious liver risks Regular liver testing is recommended during Veozah treatment to ensure early detection of potential issues Veozah was the first non-hormonal hot flash drug ...

The availability of a new non-hormonal treatment option for women with moderate to severe vasomotor symptoms addresses a substantial unmet need, providing another safe and efficacious tool to help ...

12 VEOZAH (fezolinetant film-coated tablets) is an oral, once-daily, non-hormonal medicine for the treatment of moderate to severe VMS associated with menopause. VMS are also known as hot flashes ...